COTA Signs Agreement with FDA for Breast Cancer Research
The agreement will bring real-world data to cancer treatment development.
ASHP and ASPEN Launch Professional Nutritional Support Certificate
Earn up to 19.25 hours of CE.
Lenalidomide Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes.
FDA Approves Vraylar (Cariprazine) for Bipolar Depression
New indication adds to the oral antipsychotic’s portfolio of conditions.
FDA Approves PI3K Inhibitors for Breast Cancer
First PIK3CA inhibitor treatment approved, along with diagnostic test.
New Gene Therapy for Pediatric Spinal Muscular Atrophy Approved by FDA
Zolgensma (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy
FDA Approves Sorilux (Calcipotriene) for Adolescent Plaque Psoriasis
Vitamin D analog foam indicated for topical treatment of plaque psoriasis in teens.
New Corlanor (Ivabradine) Formulation Approved by FDA
Oral solution now approved for adults and pediatric patients.
Generic VESIcare Tablets to Launch in U.S.
Update: now available from three manufacturers.
FDA Approves Nayzilam (Midazolam) for Seizure Activity in Patients with Epilepsy
Nayzilam is a benzodiazepine antiepileptic nasal spray.
FDA Approves Fragmin as First Pediatric Anticoagulant Treatment
Fragmin, a low-molecular-weight heparin dalteparin sodium injection, was approved for symptomatic venous thromboembolism.
FDA Approves Expanded Indication for Venetoclax
Venetoclax, a BCL-2 inhibitor first approved in 2016, is now indicated for chronic lymphocytic leukemia and small lymphocytic lymphoma.
New Partnership to Reduce Chronic Drug Shortages
Xellia Pharmaceuticals will manufacture essential antibiotics for Civica Rx.
Bavencio (Avelumab), Inlyta (Axitinib) Combination Approved for Advanced Renal Cell Carcinoma by FDA
Approval marks the first anti-PD-L1 therapy combination for RCC.
Eylea (Aflibercept) Injection Approved for Diabetic Retinopathy
Originally approved in 2011, aflibercept is a vascular endothelial growth factor (VEGF) inhibitor.
Ramucirumab Approved as Single Agent For Hepatocellular Carcinoma
New indication joins a series of single-agent and combination treatments for various cancers.
HHS Now Requiring Manufacturers to Disclose Drug Prices in TV Ads
Finalized rule is a step toward increasing drug pricing transparency.
Ruzurgi (Amifampridine) Approved for Rare Pediatric Autoimmune Disorder
Ruzurgi approval for rare autoimmune disorder may be an olive branch.
17th Annual Drug Take Back Day Sets New Records
Nearly 12 million pounds of medications collected since the initiative’s inception.
Kadcyla Indication Expands as Adjuvant Breast Cancer Treatment
Recent trial shows greater invasive disease-free survival when treated with Kadcyla , (ado-trastuzumab emtansine)
Qternmet XR Combinations Approved for Type-2 Diabetes
New drug combines dapagliflozin, saxagliptin, and metformin.
Walgreens Announces Mental Health First Aid Training for Pharmacists and Employees
New services will start with select pharmacists before expanding to Walgreens team memebers and potentially a nationwide resource.
Tibsovo Indication Expanded to Newly-Diagnosed Acute Myeloid Leukemia by FDA
Tibsovo (ivosidenib) is an isocitrate dehydrogenase1- inhibitor, originally approved in 2018.
Dengvaxia Approved by FDA for Prevention of Dengue Disease
First vaccine approved for all four Dengue virus serotypes in children and teens ages 9 through 16, but comes with major restrictions and controversy.
ASHP Members Honored for Practice Excellence, Leadership
Victoza (Liraglutide): Potential New Treatment for Child and Adolescent Type 2 Diabetes
Results from a recent ELLIPSE trial indicate superiority in reducing blood sugar when compared to the placebo.
Benlysta (belimumab) Indication Expanded to Children with Systemic Lupus Erythematosus (SLE)
Benlysta is the first approved treatment for children with lupus.
Eticovo (etanercept-ykro) Approved for Arthritis, Spondylitis, and Plaque Psoriasis
Eticovo (etanercept-ykro) is a TNF blocker, biosimilar to Enbrel (etanercept).
FDA’s “Reduce the Risk” Campaign Tackles Opioid Exposure
The campaign places emphasis on Americans' role in proper removal and disposal of opioids from their home.
Duobrii (halobetasol propionate and tazarotene) Moisturizing Lotion for Plaque Psoriasis
New lotion from Ortho Dermatologics expected June 2019.